Preclinical evaluation of Hematide, a novel erythropoiesis stimulating agent, for the treatment of anemia.
about
Potential of phage-displayed peptide library technology to identify functional targeting peptidesThe role of anemia management in improving outcomes for African-Americans with chronic kidney diseaseErythropoietin in stroke therapy: friend or foeDose-finding study of peginesatide for anemia correction in chronic kidney disease patients.Population pharmacokinetic and pharmacodynamic model-based comparability assessment of a recombinant human Epoetin Alfa and the Biosimilar HX575.Peginesatide for maintenance treatment of anemia in hemodialysis and nondialysis patients previously treated with darbepoetin alfaErythropoiesis-stimulating agents and other methods to enhance oxygen transport.Erythropoietic agents and the elderly.Chronic pharmacological and safety evaluation of Hematide, a PEGylated peptidic erythropoiesis-stimulating agent, in rodents.Managing dialysis patients who develop anemia caused by chronic kidney disease: focus on peginesatide.Therapeutic potential of erythropoietin and its structural or functional variants in the nervous system.Lessons learned from peginesatide in the treatment of anemia associated with chronic kidney disease in patients on dialysis.Erythropoietic stimulating agents.Erythropoietin receptor response circuitsPeginesatide and erythropoietin stimulate similar erythropoietin receptor-mediated signal transduction and gene induction events.Hematide™ for the treatment of chronic kidney disease-related anemia.Recent developments in doping testing for erythropoietin.Detection of erythropoiesis-stimulating agents in human anti-doping control: past, present and future.Differentiating factors between erythropoiesis-stimulating agents: an update to selection for anaemia of chronic kidney disease.Peginesatide for the treatment of renal disease-induced anemia.High hematocrit resulting from administration of erythropoiesis-stimulating agents is not fully predictive of mortality or toxicities in preclinical species.Erythropoiesis stimulating agents: approaches to modulate activity.Management of anemia with erythropoietic-stimulating agents in children with chronic kidney disease.New treatment approaches in chronic kidney disease-associated anaemia.Investigational therapies for renal disease-induced anemia.An overview on safety issues related to erythropoiesis-stimulating agents for the treatment of anaemia in patients with chronic kidney disease.Peginesatide for the treatment of anemia due to chronic kidney disease - an unfulfilled promiseBlocking peptides and molecular mimicry as treatment for kidney disease.Absorption, distribution, metabolism and excretion of peginesatide, a novel erythropoiesis-stimulating agent, in ratsA subchronic murine intravenous pharmacokinetic and toxicity study of Hematide™, a PEGylated peptidic erythropoiesis-stimulating agent.Population pharmacokinetics and pharmacodynamics of peptidic erythropoiesis receptor agonist (ERA) in healthy volunteers.Programmable Bio-surfaces for Biomedical Applications.Emerging drugs: mechanism of action, mass spectrometry and doping control analysis.Genotoxic assessment and toxicity evaluation of peginesatide in CByB6F1 hybrid mice.Erythropoiesis equivalence, pharmacokinetics and immune response following repeat hematide administration in cynomolgus monkeys.
P2860
Q33530848-F3077446-C3B1-43D2-80FA-8B5407DD7542Q33646679-E8DDB78D-61AD-49E5-9EA4-EA6F4A9213ABQ35548966-FFBE286B-3BA5-4721-8826-DC01860D9770Q35985899-A84DA3B6-35DF-4E44-A183-5ED951968806Q36354544-E759481B-A388-4A67-9630-440EFA66D976Q36733554-BA40A1D9-6C41-4D2A-BE51-28447904FFF1Q36736105-47AAB6E2-7679-4928-9BBA-E08F68CFB5D4Q37098040-78BF47FB-D44D-4845-88D3-B5D3C37A5F35Q37154338-8154E1ED-0B03-4EB1-97FB-8FDB090CF401Q37157237-91CD213B-B03C-4052-9C3B-6A1E9B851064Q37358669-53CBBDAE-90BC-4E93-9F99-EC16632FBA96Q37359343-6E9EBC14-7110-4814-AD90-630A9FC4C085Q37693160-71C34D55-9C14-4D8C-BA97-97B5B483F5BFQ37696206-ED5D623A-223F-4E61-BE46-B12F277D163DQ37700912-3A83F7E5-0844-4760-94A7-18C4A3938FBFQ37810076-0505F285-A873-4630-B00D-7A382514E9D9Q37884431-856EDFF7-5C59-4128-B7F3-8EA78642D295Q38029405-552EEBBC-77A4-4681-87C6-76812FDFB626Q38075798-EA9EC3FD-7971-458E-9A91-6B2724CD05C9Q38090725-4DC2C30D-CF7E-4975-8A23-4FBFC4D0CAF0Q38106921-EE5A6EA1-8400-47E4-9996-F41AF179D1D4Q38121067-40628F6F-CE97-4C07-88E6-55AFB5750B51Q38134288-799220F1-A442-4DB4-8168-17565A6D2143Q38192002-66E0E6B2-0810-48DE-A2D5-E10350C4D961Q38819455-B08BFE3A-CA3A-428F-BE74-41EAE11B0E4DQ38826645-9FDD76B0-8FA6-4FDA-9876-4B74BBA985A4Q38934661-626DAD6B-BAD8-4823-AE8F-D5660A849D1CQ38961136-FA3D5339-4F9C-431F-B87C-7DAD1E22A096Q42257325-BB6D322B-ED31-49DF-BA2C-46009DD32061Q46807825-2B9A354F-A14F-49BD-9708-22586940474EQ46891656-A014038B-9FA3-4D3E-B7FC-D38C09B3D00AQ47400920-D350644F-D03F-489D-B874-7F711C425A2AQ47992683-F5AFEB38-CBEF-4211-8B22-611BBBD8CE8EQ50041581-8855E513-9EFF-4FC7-95E8-99E197524016Q50581034-B9F24CAF-BB1E-4A01-92F6-4124507B0A12
P2860
Preclinical evaluation of Hematide, a novel erythropoiesis stimulating agent, for the treatment of anemia.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Preclinical evaluation of Hema ...... , for the treatment of anemia.
@en
type
label
Preclinical evaluation of Hema ...... , for the treatment of anemia.
@en
prefLabel
Preclinical evaluation of Hema ...... , for the treatment of anemia.
@en
P2093
P1476
Preclinical evaluation of Hema ...... t, for the treatment of anemia
@en
P2093
Christopher P Holmes
Jennifer M Green
Kei-Lai Fong
Kerstin K Leuther
Min-Jia Chen
Peter J Schatz
Richard B Mortensen
P304
P356
10.1016/J.EXPHEM.2006.05.012
P577
2006-10-01T00:00:00Z